NS 1608 | 160383-80-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: NS 1608
• 英文别名: 1-(5-chloro-2-hydroxyphenyl)-3-(3-(trifluoromethyl)phenyl)urea；1-(3-trifluoromethyl-phenyl)-3-(2-hydroxy-5-chloro-phenyl)-urea；N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-5-chlorophenyl) urea；N-(3-(Trifluoromethyl)phenyl)-N'-(2-hydroxy-5-chlorophenyl)urea；1-(5-chloro-2-hydroxyphenyl)-3-[3-(trifluoromethyl)phenyl]urea
• CAS: 160383-80-2
• 化学式: C₁₄H₁₀ClF₃N₂O₂
• 分子量: 330.694
• InChiKey: KRHJDJMOIKRPNN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  61.4
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-(三氟甲基)异氰酸苯酯 、 4-氯-2-氨基苯酚 以 四氢呋喃 为溶剂， 以96%的产率得到NS 1608
  参考文献：
  名称：

  Bioisosteric Modifications of 2-Arylureidobenzoic Acids:  Selective Noncompetitive Antagonists for the Homomeric Kainate Receptor Subtype GluR5

  摘要：

  2-Arylureidobenzoic acids (AUBAs) have recently been presented as the first series of selective noncompetitive GluR5 antagonists. In this paper we have modified the acidic moiety of the AUBAs by introducing different acidic and neutral groups, and similarly, we have replaced the urea linker of the AUBAs with other structurally related linkers. Replacing the acid with neutral substituents led to inactive compounds in all instances, showing that an acidic moiety is necessary for activity. Replacing the carboxylic moiety in 2a with a sulfonic acid (5c) or a tetrazole ring (5d) improved the potency at GluR5 receptors (compounds 5c and 5d showed IC50 values of 1.5 and 2.0 muM, respectively, compared to compound 2a with IC50 = 4.8 muM). Compound 5c did not show improved in vivo activity in the ATPA rigidity test compared to 2a, whereas compound 5d was 4 times more potent than 2a. All compounds wherein the urea linker had been replaced showed lower or no activity. The results described extend the knowledge of structure-activity relationships for the AUBAs, and compound 5d may prove to be a good candidate for studying GluR5 receptors in vitro and in vivo.

  DOI：

  10.1021/jm030638w

文献信息

• [EN] ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES<br/>[FR] OUVREURS DU CANAL ERG DESTINES AU TRAITEMENT DE MALADIES NEURONALES LIEES A L'HYPEREXCITABILITE
  申请人：POSEIDON PHARMACEUTICALS AS

  公开号：WO2005023238A1

  公开（公告）日：2005-03-17

  This invention relates to the use of ERG channel openers for the treatment of hyperexcitability-related neuronal diseases, and to the use of specific compounds for such treatment. In a separate aspect the invention provides novel compounds useful as ERG channel openers.

  本发明涉及使用ERG通道开放剂治疗与高兴奋性有关的神经疾病，以及使用特定化合物进行此类治疗。在另一个方面，本发明提供了新型化合物，可用作ERG通道开放剂。
• [EN] ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS<br/>[FR] SUBSTANCES D'OUVERTURE DES CANAUX ERG POUR LE TRAITEMENT D'ARYTHMIES CARDIAQUES
  申请人：POSEIDON PHARMACEUTICALS AS

  公开号：WO2005023237A1

  公开（公告）日：2005-03-17

  This invention relates to the use of ERG channel openers for the treatment of cardiac arrhythmias, and to the use of specific compounds for such treatment. In a separate aspect the invention provides novel compounds useful as ERG channel openers.

  本发明涉及使用ERG通道开放剂治疗心律失常，以及使用特定化合物进行此类治疗。在另一个方面，本发明提供了用作ERG通道开放剂的新化合物。
• TRAUMA THERAPY
  申请人：Dobson Geoffrey Philip

  公开号：US20090324748A1

  公开（公告）日：2009-12-31

  The invention provides a method of reducing injury to cells, tissues or organs of a body following trauma by administering a composition to the body following trauma, including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and (ii) a local anaesthetic. Also provided is a composition for reducing injury to cells, tissues or organs of a body following trauma including: (i) and (ii). The composition may be hypertonic.

  本发明提供了一种减少创伤后身体细胞、组织或器官受损的方法，包括在创伤后向身体注射一种组合物，其中包括：（i）一个钾通道开放剂或激动剂和/或腺苷受体激动剂；和（ii）一个局部麻醉剂。同时提供了一种用于减少创伤后身体细胞、组织或器官受损的组合物，包括（i）和（ii）。该组合物可以是高渗的。
• Erg channel openers for the treatment of cardiac arrhythmias
  申请人：Olesen Peter Soren

  公开号：US20060281794A1

  公开（公告）日：2006-12-14

  This invention relates to the use of ERG channel openers for the treatment of cardiac arrhythmias, and to the use of specific compounds for such treatment. In a separate aspect the invention provides novel compounds useful as ERG channel openers.

  本发明涉及使用ERG通道开放剂治疗心律失常，并涉及使用特定化合物进行此类治疗。在另一个方面，本发明提供了新的化合物，可用作ERG通道开放剂。
• Diphenylurea Derivatives Useful As Potassium Channel Activators
  申请人：Dahl H. Bjarne

  公开号：US20070293553A1

  公开（公告）日：2007-12-20

  The present invention relates to the medical use of a certain group of diphenyl urea derivatives as potassium channel blockers for treating cardiovascular diseases, an obstructive or inflammatory airway disease, urinary incontinence, psychosis, epilepsy or pain, or for facilitating the blood-brain barrier permeability for other therapeutic substances. In other aspects the invention relates to the use of these compounds in a method of therapy.

  本发明涉及使用某些二苯基脲衍生物作为钾通道阻滞剂，用于治疗心血管疾病、阻塞性或炎性气道疾病、尿失禁、精神病、癫痫或疼痛，或用于促进其他治疗物质通过血脑屏障的渗透。在其他方面，本发明涉及这些化合物在治疗方法中的使用。